Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,724 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,600 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02818920 | Neoadjuvant Pembrolizumab(TOP 1501) | completed | Phase 2 | 35 | Neal Ready MD PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03313804 | Priming Immunotherapy in Advanced Disease With Radiation | completed | Phase 2 | 76 | John L. Villano, MD, PhDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04332653 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors |
| completed |
| Phase 1 / Phase 2 |
| 215 |
| NeoImmuneTechINDUSTRY |
| 1 |
| Mar 9, 2026 |
| clinicaltrials |
| NCT03083041 | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 210 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04900363 | A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC | completed | Phase 1 / Phase 2 | 108 | AkesoINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05263947 | Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation | completed | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02513563 | AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | completed | Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02523469 | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 67 | Medical University of South CarolinaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02917993 | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Incyte CorporationINDUSTRY | 4 | Feb 9, 2026 | clinicaltrials |
| NCT04184921 | Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients | completed | Phase 2 | 216 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05429320 | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT01897480 | A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations(Balise) | completed | Phase 2 | 168 | Eli Lilly and CompanyINDUSTRY | 9 | Jan 26, 2026 | clinicaltrials |
| NCT03003468 | Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | completed | Phase 1 / Phase 2 | 35 | Lawrence Feldman, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03285321 | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 105 | Greg Durm, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05001971 | Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy | completed | Phase 2 | 65 | Hunan Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 92 | ExelixisINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04452877 | A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | completed | Phase 2 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02442349 | Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific(AURA17) | completed | Phase 2 | 171 | AstraZenecaINDUSTRY | 3 | Jan 9, 2026 | clinicaltrials |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | completed | Phase 2 | 47 | Revolution Medicines, Inc.INDUSTRY | 10 | Jan 6, 2026 | clinicaltrials |
| NCT06029127 | A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | BeiGeneINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT02473133 | Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC(RTEP7) | completed | Phase 2 | 158 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04224337 | Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma | completed | Phase 2 | 16 | Seoul National University HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05465343 | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) | completed | Phase 2 | 24 | Peking Union Medical CollegeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04965090 | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02314364 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | completed | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT03836066 | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients(TELMA) | completed | Phase 2 | 41 | Fundación GECPOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05440916 | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer(PRIMM) | completed | Phase 2 | 50 | University Medical Centre MariborOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05664971 | JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 119 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05346380 | Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download | completed | Phase 1 / Phase 2 | 38 | Massachusetts General HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03132532 | Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04644237 | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)(DESTINY-LUNG02) | completed | Phase 2 | 152 | Daiichi SankyoINDUSTRY | 10 | Nov 21, 2025 | clinicaltrials |
| NCT01186861 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 9 | Nov 18, 2025 | clinicaltrials |
| NCT01221077 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | completed | Phase 2 | 88 | Astellas Pharma IncINDUSTRY | 6 | Nov 18, 2025 | clinicaltrials |
| NCT01847209 | Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions | completed | Phase 2 | 25 | Brigham and Women's HospitalOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03916419 | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer | completed | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02823990 | TG4010 and Nivolumab in Patients With Lung Cancer | completed | Phase 2 | 13 | Megan Daly, MDOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02316002 | Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 51 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03909971 | A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China | completed | Phase 2 | 109 | PfizerINDUSTRY | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03573947 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC(TOP1705) | completed | Phase 2 | 46 | Jeffrey ClarkeOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04108026 | Immunotherapy in Patient With Poor General Condition(SAVIMMUNE) | completed | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05386888 | A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | completed | Phase 2 | 65 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2026source: clinicaltrials